|
Pergolide (trade name Permax) is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with low levels of the neurotransmitter dopamine in the brain. Pergolide has some of the same effects as dopamine in the body. In 2007 pergolide was withdrawn from the U.S. market for human use after several published studies revealed a link between the drug and increased rates of valvular heart disease.〔(FDA Public Health Advisory: Pergolide (marketed as Permax) )〕 However, a veterinary form of pergolide (trade name Prascend) is permitted for the treatment of Pituitary Pars Intermedia Dysfunction (PPID) also known as equine Cushing's syndrome (ECS) in horses.〔()〕 == Indications == Pergolide is not available for use by humans in the United States, however it is still used in various other countries, where it is used to treat various conditions including Parkinson's disease, hyperprolactinemia, and restless leg syndrome. Furthermore, pergolide may also be used for veterinary purposes. Under the trade name Prascend, manufactured by Boehringer Ingelheim,〔http://www.valleyvet.com/ct_detail.html?pgguid=e0f4888c-86de-4ce9-9013-6d947df697a8&gas=pergolide%20mesylate〕 it is commonly used for the treatment of pituitary pars intermedia hyperplasia or Equine Cushing's Syndrome (ECS) in horses.〔(【引用サイトリンク】title=Pergolide For Veterinary Use )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Pergolide」の詳細全文を読む スポンサード リンク
|